BioCentury on BioBusiness,
Idenix nucleotide analog fills Merck gap in race for pan-genotype HCV regimen
Related tables, figures and sidebars
Nucleotide arms race
Monday, June 16, 2014
The acquisition of Idenix
Pharmaceuticals Inc. will fill a hole in Merck
& Co. Inc.'s HCV toolbox and give the pharma a chance to develop an
interferon-free regimen that can treat all patients at the same dose regardless
of HCV genotype, HIV co-infection or other co-morbidities.
The $3.9 billion acquisition will put Merck in second place
Sciences Inc. in the race to develop a pan-genotype regime. But the
pharma thinks its combination will have a shorter duration of therapy than the
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]